What Happened?
South San Francisco, CA-based Vaxart Appointed Raymond Stapleton as Chief Technology Officer
Date of management change: August 31, 2022
South San Francisco, CA-based Vaxart Appointed Raymond Stapleton as Chief Technology Officer
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Raymond Stapleton is Chief Technology Officer at Vaxart. Previously, Raymond held various senior IT leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Weiler Mark, Zhong Ling, Lypka Laura, Wood Tom, Haas Sue, Recla Jason, Keisler Trey, Villasis Simon, Michalczyk Artur, Mann Joe, Dickey Bruce
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.